

**Amendments to the Claims:**

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) ~~A~~-An injectable pharmaceutical composition containing 8 to 16 mg/mL of glycyrrhizin, 3 to 6 mg/mL of cysteine and 80 to 160 mg/mL of aminoacetic acid wherein substantially no sulfite is contained in the pharmaceutical composition.

2. (Canceled)

3. (Currently Amended) The injectable pharmaceutical composition according to claim 1, wherein glycyrrhizin is monoammonium glycyrrhizinate.

4. (Currently Amended) The injectable pharmaceutical composition according to claim 1, wherein cysteine is cysteine hydrochloride.

5-8. (Canceled)

9. (Currently Amended) The injectable pharmaceutical composition according to claim 1, wherein the concentration of cysteine is more than 70% after the composition is stored at 60°C for 14 days.

10. (Currently Amended) ~~A~~-An injectable pharmaceutical composition containing 8 to 16 mg/mL (as glycyrrhizin) of monoammonium glycyrrhizinate, 4 to 8 mg/mL of cysteine hydrochloride and 80 to 160 mg/mL of aminoacetic acid, wherein substantially no sulfite is contained in the pharmaceutical composition.

11. (Withdrawn-Currently Amended) A method of treating hepatic diseases comprising: administering intravenously to a patient ~~a~~-an injectable pharmaceutical composition containing 8 to 16 mg/mL of glycyrrhizin, 3 to 6 mg/mL of cysteine and 80 to 160 mg/mL of aminoacetic acid, wherein substantially no sulfite is contained in the pharmaceutical composition.

12. (Withdrawn-Currently Amended) A method of treating allergy comprising:  
administering intravenously to a patient ~~a~~an injectable pharmaceutical composition  
containing 8 to 16 mg/mL of glycyrrhizin, 3 to 6 mg/mL of cysteine and 80 to 160 mg/mL of  
aminoacetic acid, wherein substantially no sulfite is contained in the pharmaceutical  
composition.

13. (Withdrawn-Currently Amended) A method of treating hepatic diseases  
comprising: administering intravenously to a patient ~~a~~an injectable pharmaceutical  
composition containing 8 to 16 mg/mL (as glycyrrhizin) of monoammonium glycyrrhizinate,  
4 to 8 mg/mL of cysteine hydrochloride and 80 to 160 mg/mL of aminoacetic acid, wherein  
substantially no sulfite is contained in the pharmaceutical composition.

14. (Withdrawn-Currently Amended) A method of treating allergy comprising:  
administering intravenously to a patient ~~a~~an injectable pharmaceutical composition  
containing 8 to 16 mg/mL (as glycyrrhizin) of monoammonium glycyrrhizinate, 4 to 8 mg/mL  
of cysteine hydrochloride and 80 to 160 mg/mL of aminoacetic acid, wherein substantially no  
sulfite is contained in the pharmaceutical composition.